1 / 24
Murakami Lab, May 2025
2 / 24
Nina Xiong and Taiyang Chen presenting “Access to Diagnosis through Liquid Biopsy (ADLiB): expediting lymphoma diagnosis in a high-need setting” at the Hematologic Neoplasia & Immunologic Therapies Seminar, May 2025
3 / 24
Chase Weizer presenting his poster at 2025 AACR in Chicago, IL
4 / 24
Last week in the lab for summer students Rahaf and
Sophie ☹, August 2025 (Left to right: Rahaf Qarabsa, Sophie Zhu, Alyssa Wu, Claire Walter, Emily Sumpena)
5 / 24
Emily Sumpena smiling her way through tissue culture work, August 2025
6 / 24
Luzany Correia presenting his work at the End of
Summer CURE Presentation, August 2025
7 / 24
End of Summer CURE Presentation by Ashreen Williams, August 2025
8 / 24
Rahaf Qarabsa getting down to business, August 2025
9 / 24
Lab outing to Island Creek Oyster Farm, June 2025
10 / 24
Oyster shucking at Island Creek Oyster Farm, June 2025
11 / 24
Alyssa Wu locking in, August 2025
12 / 24
Dr. Mark Murakami presenting “Ph+ Acute Lymphoblastic
Leukemia: Dual TKI Therapy and Pathways of Resistance” at Hematologic Neoplasia & Immunologic Therapies Seminar, May 2025
13 / 24
Lunch with the Parry Lab, May 2025
14 / 24
Goodbye, Nina ☹ (we miss you!)
15 / 24
Claire Walter showing Rahaf Qarabsa how to process
primary samples, August 2025
16 / 24
Murakami Lab, December 2024
17 / 24
Congratulations to Taiyang Chen on her excellent
capstone presentation for the HMS Biomedical Informatics Master's Program in December 2024! (Left to right: Nina Xiong, Taiyang Chen, Mark Murakami)
18 / 24
Dr. Mark Murakami, Dr. Katherine Antel, Dr. Lydie
Debaize, and Dr. Mingzeng Zhang (clockwise) grabbing lunch at 2023 AACR in Orlando, FL!
19 / 24
Murakami Lab, Summer 2023
20 / 24
Going away for Dr. Katherine Antel ☹, September 2023
21 / 24
Lunch with the Pikman Lab, June 2023
22 / 24
Summer outing in Fenway, July 2022
23 / 24
Lab lunch in Fenway, July 2022
24 / 24
End of Summer CURE Presentation by Mia Blennau,
August 2022
About
The Murakami Lab at DFCI studies minimal residual disease in B-cell leukemia and lymphoma
and aims to translate mechanistic discoveries into individualized therapies to improve patient outcomes
by utilizing our repository of preclinical models including patient-derived xenograft (PDX) mouse models,
access to conventional and experimental therapeutic agents,
expertise in lymphoid genomics and bioinformatics, novel single-cell biophysical and molecular profiling platforms,
and involvement in early phase clinical trials.